GSK has highlighted approval of Nucala in COPD as one of its top 2025 priorities, adding to its established medicines for the ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic ...

With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

Virtual pulmonary rehabilitation is a safe, effective alternative to traditional pulmonary rehabilitation programs for people ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

Researchers have identified in a new study that sole e-cigarette use is strongly linked with the risk of chronic obstructive ...

Researchers have developed a novel rat model that closely replicates the pathological features and physiological changes ...

Virtual pulmonary rehabilitation is a safe, effective alternative to traditional pulmonary rehabilitation programs for people ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...